GAMMA Investing LLC Raises Holdings in Inhibrx, Inc. (NASDAQ:INBX)

GAMMA Investing LLC boosted its position in Inhibrx, Inc. (NASDAQ:INBX) by 9,834.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,855 shares of the company’s stock after purchasing an additional 6,786 shares during the period. GAMMA Investing LLC’s holdings in Inhibrx were worth $960,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. PNC Financial Services Group Inc. purchased a new stake in Inhibrx in the 4th quarter worth approximately $28,000. Natixis purchased a new stake in Inhibrx in the 4th quarter worth approximately $31,000. New York State Common Retirement Fund purchased a new stake in Inhibrx in the 4th quarter worth approximately $53,000. State of Wyoming purchased a new stake in Inhibrx in the 4th quarter worth approximately $83,000. Finally, Corebridge Financial Inc. purchased a new stake in Inhibrx in the 4th quarter worth approximately $89,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Inhibrx Stock Performance

Shares of NASDAQ INBX opened at $14.62 on Tuesday. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $17.79. The firm has a market cap of $211.64 million and a price-to-earnings ratio of 0.13. The stock’s 50-day simple moving average is $12.55 and its 200-day simple moving average is $13.40.

Inhibrx (NASDAQ:INBX) last announced its earnings results on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.55) by ($0.25). As a group, research analysts predict that Inhibrx, Inc. will post 104.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research note on Thursday, May 15th.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.